Fed. Circ. Upholds Eisai’s Aciphex Patent
The U.S. Court of Appeals for the Federal Circuit determined Monday that a district court properly found that Israel-based Teva and India-based Dr. Reddy’s failed to prove that Eisai’s patent was invalid for obviousness or unenforceable due to inequitable conduct.
The unanimous decision by...
To view the full article, register now.